Patient Guide: A Randomized, Open-Label, Multicenter, Phase 2 Study Evaluating the Efficacy and Safety of Zilovertamab Vedotin (MK-2140) Plus R-CHP Versus Polatuzumab Vedotin Plus R-CHP in Treatment-Naïve Participants with GCB Subtype of Diffuse Large B-Cell Lymphoma

We'll Help You Connect with This Trial

Quri.ai is a free clinical trial matching service. We help patients like you connect directly with research sites conducting this study.

  • Get matched to the right study location for you
  • Connect directly with study coordinators at multiple participating sites
  • Understand eligibility with our simplified screening tool
  • Free service - we're here to help you access clinical research
Trial ID: NCTMK-2140-011-00
Status: 🟢 Enrolling Now
Condition: Cancer, Lymphoma, Hematologic/Blood Related Cancers
Phase: PHASE2

Loading interactive enrollment tools...

The full interactive experience will load momentarily